Xl228: A Phase 1 Dose Escalation Study Of The Safety, Pharamacokinetics, And
Xl228: A Phase 1 Dose Escalation Study Of The Safety, Pharamacokinetics, And | |
|---|---|
| Sponsor(s) | Exelixis |
| Principal Investigator(s) | John Kauh, MD |
| Dates | 10/27/2009 - 10/27/2013 |
Xl228: A Phase 1 Dose Escalation Study Of The Safety, Pharamacokinetics, And | |
|---|---|
| Sponsor(s) | Exelixis |
| Principal Investigator(s) | John Kauh, MD |
| Dates | 10/27/2009 - 10/27/2013 |
